This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OSMT Osmotica Pharmaceuticals (OSMT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Osmotica Pharmaceuticals Stock (NASDAQ:OSMT) Get OSMT alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.98▼$1.4952-Week Range N/AVolume296,500 shsAverage Volume396,682 shsMarket Capitalization$69.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ. Read More Receive OSMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Osmotica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OSMT Stock News HeadlinesVanda Pharmaceuticals Inc.March 6, 2024 | wsj.comRVL Pharmaceuticals PLC (RVLPQ)December 19, 2023 | investing.comThe 7 Warning Signals Flashing Red Right NowA free report revealing the 7 key indicators that have predicted every major economic collapse since 1929. Right now, all seven are flashing red simultaneously for the first time since 2007. These aren't the signals you'll see on CNBC.October 23 at 2:00 AM | American Alternative (Ad)Osmotica Pharmaceuticals is about to announce its earnings — here's what to expectAugust 14, 2023 | markets.businessinsider.comWhat Wall Street expects from Osmotica Pharmaceuticals's earningsMarch 19, 2023 | markets.businessinsider.comGRO Biosciences Appoints Rakhshita Dhar to its Board of DirectorsJanuary 19, 2022 | nz.finance.yahoo.comUPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales GuidanceJanuary 19, 2022 | finance.yahoo.comOsmotica Pharmaceuticals Announces Corporate Name Change to RVL Pharmaceuticals plc With New Ticker Symbol 'RVLP'January 19, 2022 | benzinga.comSee More Headlines OSMT Stock Analysis - Frequently Asked Questions How were Osmotica Pharmaceuticals' earnings last quarter? Osmotica Pharmaceuticals plc (NASDAQ:OSMT) released its earnings results on Monday, November, 15th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.06. The business earned $2.20 million during the quarter, compared to analysts' expectations of $2.39 million. Osmotica Pharmaceuticals had a negative trailing twelve-month return on equity of 81.23% and a negative net margin of 138.76%. When did Osmotica Pharmaceuticals IPO? Osmotica Pharmaceuticals (OSMT) raised $58 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 8,300,000 shares at a price of $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities acted as the underwriters for the IPO. What other stocks do shareholders of Osmotica Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Osmotica Pharmaceuticals investors own include Canopy Growth (CGC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), NIO (NIO), Allena Pharmaceuticals (ALNA) and Endo International (ENDP). Company Calendar Last Earnings11/15/2021Today10/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:OSMT CIK1739426 Webwww.osmotica.com Phone(908) 809-1300FaxN/AEmployees302Year Founded2000Profitability EPS (Trailing Twelve Months)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.59 million Net Margins-138.76% Pretax Margin-167.59% Return on Equity-81.23% Return on Assets-20.97% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.42 Sales & Book Value Annual Sales$177.88 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.00 Book Value$1.50 per share Price / BookN/AMiscellaneous Outstanding Shares62,585,000Free Float59,318,000Market Cap$69.47 million OptionableNot Optionable Beta2.34 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:OSMT) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Osmotica Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Osmotica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.